FDA-approved1,2,3Evidence: Large human trialsMetabolic and weight

Insulin glargine-aldy1

Also called Langlara1

Key takeaway

Insulin glargine-aldy is a long-acting insulin, sold as Langlara, that FDA licensed on April 29, 2026 to improve blood-sugar control in adults and children with diabetes.1,2,3 Its label states that Langlara is biosimilar to Lantus (insulin glargine), meaning it was approved on data showing it is highly similar to Lantus with no clinically meaningful differences.1 The clinical trials in its label are the insulin glargine trials against NPH insulin, which the Lantus label describes as trials of Lantus. No trial run with insulin glargine-aldy itself is described in the sources reviewed here.1,4

Insulin glargine-aldy at a glance

What it isA long-acting insulin glargine product that its label states is biosimilar to Lantus. The label states that insulin lowers blood sugar by helping muscle and fat take up glucose and by reducing the liver’s glucose output.1
FDA statusFDA-approved. Drugs@FDA lists Langlara, application BLA761412, with an approval date of April 29, 2026. The cited label has no boxed warning.1,2
Human evidenceLarge randomized trials of Lantus, the reference product, compared with NPH insulin. The Langlara label summarizes them as insulin glargine studies; they are not trials of insulin glargine-aldy.1,4
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is insulin glargine-aldy?

Insulin glargine-aldy is an insulin glargine product, a lab-made long-acting form of insulin. Drugs@FDA lists it as Langlara, from Sunshine Lake Pharma, under application BLA761412.1,2

FDA’s approval letter states that the application was submitted under section 351(k) of the Public Health Service Act and describes it as seeking licensure as biosimilar to and interchangeable with US-licensed Lantus.3

The Langlara label states that it is biosimilar to Lantus, and explains that a biosimilar is approved on data showing it is highly similar to an FDA-approved reference product with no clinically meaningful differences.1

How does insulin glargine-aldy work?

The label states that the main action of insulin, including insulin glargine products, is to regulate glucose metabolism.1

According to the label, insulin lowers blood sugar by stimulating glucose uptake, especially by muscle and fat, and by reducing glucose production by the liver.1

What do human studies show?

The Langlara label summarizes open-label, randomized trials that compared insulin glargine with NPH insulin in 2,327 adults and 349 children with type 1 diabetes and 1,563 adults with type 2 diabetes.1

The Lantus label describes the same trials, with the same numbers, as trials of Lantus. They are the reference product’s trials, not trials of insulin glargine-aldy.1,4

In general, the reduction in HbA1c, a measure of long-term blood sugar, with insulin glargine was similar to that with NPH insulin, according to both labels.1,4

What the evidence base contains

  • Large randomized human trial Open-label randomized trials of insulin glargine compared with NPH insulin in 2,327 adults and 349 children with type 1 diabetes and 1,563 adults with type 2 diabetes. The Langlara label summarizes them, and the Lantus label describes the same trials, with the same numbers, as trials of Lantus, the reference product. The largest single trial enrolled 619 adults.1,4

Evidence-strength label: Large randomized human trials. How this label is assigned

Is insulin glargine-aldy FDA-approved?

Yes. Drugs@FDA lists Langlara, application BLA761412, with an approval date of April 29, 2026.2

FDA’s approval letter licenses Langlara and states that it is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.3

The Langlara label cited here (DailyMed SPL version 5, published July 8, 2026) states the same indication, states that Langlara is biosimilar to Lantus, and states that it is not recommended for treating diabetic ketoacidosis.1

The label has no boxed warning. It states that the product is contraindicated during episodes of low blood sugar and in people allergic to any insulin glargine product or its ingredients.1

Its warnings cover low or high blood sugar after changes in insulin treatment, low blood sugar including from medication errors, allergic reactions, low potassium, and fluid retention and heart failure when used with PPAR-gamma agonists.1

Timeline

  1. FDA approves Langlara, according to Drugs@FDA and FDA’s approval letter.2,3
  2. DailyMed publishes the Langlara label version cited on this page.1

What is still unknown?

The data behind FDA’s decision: Drugs@FDA lists no review documents for this application, and the approval letter does not set out its findings.2,3

Whether FDA found Langlara interchangeable with Lantus: the approval letter says the application sought that, but the label cited here states only that it is biosimilar.1,3

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Insulin glargine-aldy: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Insulin glargine-aldy are the records PeptideScanner has selected and published, not every registration or paper about Insulin glargine-aldy. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Langlara. Its label states that it is biosimilar to Lantus. The trials in the label are the insulin glargine trials against NPH insulin, which the Lantus label describes as trials of Lantus; no trial of insulin glargine-aldy itself is described in the sources reviewed here.↗↗↗↗

Status sources checked through July 22, 2026. See status sources and coverage →

What does the U.S. product label say?

Langlara · Read September 15, 2026 · Preserved label summary 1

Which population and use does the label cover?

The cited Langlara label covers glycemic control in adults and children with diabetes mellitus. It does not cover treatment of diabetic ketoacidosis. Label: 1 ↗

What clinical studies does the label describe?

Section 14 summarizes open-label randomized comparisons of insulin glargine with NPH insulin involving 2,327 adults and 349 children with type 1 diabetes and 1,563 adults with type 2 diabetes. HbA1c reductions were generally similar. These are the label’s insulin-glargine clinical studies, not a count of trials conducted specifically with insulin glargine-aldy. Label: 14.1, 14.2, 14.3 ↗

Which safety limits matter?

The label describes potentially life-threatening hypoglycemia, severe hypersensitivity, low potassium, medication errors and fluid retention or heart failure with thiazolidinediones. Hypoglycemia episodes and relevant hypersensitivity are contraindications. Label: 4, 5 ↗

Label edition and source pins

U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.

LANGLARA (insulin glargine-aldy) injection, solution · SPL version 5 · published 2026-07-08

Label ZIP SHA-256: c393585bbdb741f3ff47b5db3b45ed1dfc84a10d2d03e83796d8aae94d3ad187. Extracted XML SHA-256: a785c2958a54aeb8984fecab009a9c899d5b73479104b4d2ae4982ac6f32f770.

Open versioned label context data →

What remains unresolved?

This account summarizes the cited product label. A separate appraisal of the complete clinical literature and other jurisdictions remains open.

Official-source readings

Inside the official reviews

Reviewed 2026-09-19 · Preserved version 1

The approval is tied to an exact biosimilar identity

FDA’s April 2026 letter licenses Langlara, insulin glargine-aldy, under BLA 761412. The reference product is US-Lantus; this should not be confused with other insulin-glargine suffixes or applications. FDA PDF pp. 1 ↗

More findings, study links and document coverage

Biosimilarity and interchangeability are product-specific findings

The letter addresses the specified Langlara presentation as biosimilar to and interchangeable with the specified US-Lantus presentation. It is not a ranking of all insulin products or permission to treat their presentations as identical. FDA PDF pp. 1 ↗

The letter and clinical-trial evidence serve different purposes

This approval letter records a licensing decision and the glycemic-control indication. It does not supply a trial-level comparative efficacy analysis; the separate label account explains which insulin-glargine studies its label summarizes. FDA PDF pp. 1 ↗

Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.

Document coverage

Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.

One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗

Inspect documents, application identities and source pins

Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.

  • Langlara: FDA approval letter ↗

    Selected sections reviewed · fda-langlara-approval-2026 · Document/feed date: 2026-04-29

    Application identity and document date were checked in the PDF, independently of the URL year or candidate feed association.

    Verified: Langlara · BLA 761412 · Document dated 2026-04-29. Identity checked on PDF pp. 1, 6.

    Approval-letter identity, licensing language and signature date only. This is not a clinical-review or trial-level appraisal.

    Retrieved 2026-09-19. Read PDF pages: 1, 6 of 6. SHA-256: ef59f1e69d9b3f9045e067d76c1c602dac9f20ab90520c2e7535832db50ab5dc.

Remaining work

  • Locate and read the product-specific biosimilarity and interchangeability review behind BLA 761412.
  • Reconcile current branded and unbranded labeling without assigning evidence from a different insulin-glargine suffix.

Open versioned document coverage and study pins →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Scoped peptide/product-name PubMed query. The aldy-specific query does not search the full parent insulin glargine literature.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

aldy[All Fields] AND insulin[All Fields]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:07:09.030685+00:00 · HTTP 200 · SHA-256 1e01cb15bf53366528ed59074e9f9113c824ed986d99842df0a81b323fa1e6e3.

  • A scoped product-label account is available separately; it is not an independent literature review.
  • Other aliases, parent molecules, study-family linkage and full-text appraisal remain separate work.
  • Zero aldy-and-insulin name matches do not mean zero human evidence. The product label draws on reference insulin glargine studies; those parent studies must not be described as trials conducted specifically with the biosimilar.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    FDA search

    Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

    1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    products.active_ingredients.name:"INSULIN GLARGINE-ALDY"

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:10:16.355362+00:00 · HTTP 200 · SHA-256 9d9b9554d36dad7859e00002365c43768fc72d347d3226e47be96c436e4ab0fb.

    • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
    • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

    Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    1. FDA BLA761412 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: INSULIN GLARGINE-ALDY.

    EMA search

    Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

    0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary identity terms: ["Insulin glargine-aldy", "Langlara"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

    • Document appraisal and national European sources remain open.
    • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

    Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      EMA search

      Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

      0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary identity terms: ["Insulin glargine-aldy", "Langlara"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

      • Document appraisal and national European sources remain open.
      • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

      Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        EMA search

        Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

        0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

        Search terms, record decisions and remaining work

        Case-insensitive word-boundary identity terms: ["Insulin glargine-aldy", "Langlara"]

        Source retrievals and payload pins
        • Open the source endpoint ↗

          Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

        • Document appraisal and national European sources remain open.
        • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

        Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

          ClinicalTrials.gov search

          ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

          0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

          Search terms, record decisions and remaining work

          "Insulin glargine-aldy" OR "Langlara"

          Source retrievals and payload pins
          • Open the source endpoint ↗

            Retrieved 2026-09-15T11:26:14.448759+00:00 · HTTP 200 · SHA-256 b54968c05ff881a1ef7ce604b6a340248f8e2aee8637bef06da0f5693f520df8.

          • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
          • Other registries, unregistered studies and additional aliases remain outside this query.

          Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

            Explore status sources, recent additions, and coverage gaps

            Living status brief

            What is the current status of Insulin glargine-aldy?

            FDA-approved as Langlara. Its label states that it is biosimilar to Lantus. The trials in the label are the insulin glargine trials against NPH insulin, which the Lantus label describes as trials of Lantus; no trial of insulin glargine-aldy itself is described in the sources reviewed here.↗↗↗↗

            The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

            Evidence present

            What records are connected here?

            Evidence lanes
            1
            Source years
            1
            Drugs@FDA applications
            1

            These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

            Coverage gaps

            What remains unknown or unsupported?

            PeptideScanner currently has no selected clinical trial records, PubMed literature metadata records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

            PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

            Explore the Evidence Map and record counts

            Evidence Map v1

            What kinds of records connect to Insulin glargine-aldy?

            Compare collection coverage →

            This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

            6Selected dated records
            9Connected citations
            1Populated source years2026
            1/4Record lanes present

            Registered human studies

            Trial composition

            0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

            PubMed bibliography

            Publication composition

            0 of 0 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

            Regulatory and publication surfaces

            What is structurally connected?

            Drugs@FDA applications
            1
            FDA Federal Register documents
            0
            DailyMed SPL versions
            5
            Canonical profile
            Published
            Profile structured data
            Published
            Linked dated records
            6

            Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

            Profile publication history and record counts
            Source records by collection · 6 dated records

            Research hub

            Explore the Insulin glargine-aldy evidence record

            Open all 6 records →
            6Dated records
            1Evidence type
            6Cited public sources
            1Source year

            Change ledger

            Recently changed for Insulin glargine-aldy

            Open all 9 events →

            PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

            Profile updated

            Insulin glargine-aldy profile

            We now state that the label calls Langlara biosimilar to Lantus, and that the trials in its label are the reference product’s trials, which the Lantus label describes as trials of Lantus. We also no longer suggest that an unread page of the approval letter might hold FDA’s findings: it does not.

            PeptideScanner change date
            November 16, 2026
            Evidence lane
            Profile
            Record added

            Insulin glargine-aldy DailyMed SPL version 6

            DailyMed lists Structured Product Labeling version 6 for the reviewed Insulin glargine-aldy label family with a published date of 2026-09-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

            PeptideScanner change date
            November 15, 2026
            Cited source date
            September 21, 2026
            Evidence lane
            Regulatory
            Record added

            Insulin glargine-aldy DailyMed SPL version 7

            DailyMed lists Structured Product Labeling version 7 for the reviewed Insulin glargine-aldy label family with a published date of 2026-10-19. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

            PeptideScanner change date
            November 15, 2026
            Cited source date
            October 19, 2026
            Evidence lane
            Regulatory

            Official-source collections

            Source records for Insulin glargine-aldy

            Open the full research atlas →
            DailyMed SPL history5

            Version metadata and exact historical ZIP receipts for the reviewed label family, without reproducing or interpreting label text.

            1. SPL version 7Published 2026-10-19 · ZIP SHA-256 6a2c16b5734f…
            2. SPL version 6Published 2026-09-21 · ZIP SHA-256 4f6f4e4d9f8c…
            3. SPL version 5Published 2026-07-08 · ZIP SHA-256 c393585bbdb7…
            4. SPL version 2Published 2026-06-05 · ZIP SHA-256 bf128c04b915…
            5. SPL version 1Published 2026-06-02 · ZIP SHA-256 2bbc3dd0e7ba…
            Explore all DailyMed label versions →

            Evidence types

            Coverage by source year

            Selected records span April 29, 2026 to October 19, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

            Continue exploring

            Profiles with overlapping source-year coverage

            Open the research atlas →

            These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

            Organizations and trial records named in cited sources

            Organizations named in cited records

            • U.S. National Library of Medicine1
            • U.S. Food and Drug Administration2,3
            Dated updates connected to this profile · 6

            Updates connected to this profile

            Open the full cross-source timeline →
            1. Regulatory

              Insulin glargine-aldy DailyMed SPL version 7↗

              DailyMed lists Structured Product Labeling version 7 for the reviewed Insulin glargine-aldy label family with a published date of 2026-10-19. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗

            2. Regulatory

              Insulin glargine-aldy DailyMed SPL version 6↗

              DailyMed lists Structured Product Labeling version 6 for the reviewed Insulin glargine-aldy label family with a published date of 2026-09-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗

            3. Regulatory

              Insulin glargine-aldy DailyMed SPL version 5↗

              DailyMed lists Structured Product Labeling version 5 for the reviewed Insulin glargine-aldy label family with a published date of 2026-07-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗

            4. Regulatory

              Insulin glargine-aldy DailyMed SPL version 2↗

              DailyMed lists Structured Product Labeling version 2 for the reviewed Insulin glargine-aldy label family with a published date of 2026-06-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗

            5. Regulatory

              Insulin glargine-aldy DailyMed SPL version 1↗

              DailyMed lists Structured Product Labeling version 1 for the reviewed Insulin glargine-aldy label family with a published date of 2026-06-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗

            6. Regulatory

              Drugs@FDA application BLA761412↗

              The official Drugs@FDA dataset lists original submission 1 for BLA 761412 with status AP dated 2026-04-29, and names insulin glargine-aldy among the application record's active ingredients.↗

            Citations

            Sources

            Coverage and sources →

            Numbered markers in the text point here. Each link opens the original public record.

            1. 1
              LANGLARA (insulin glargine-aldy) injection, solution · SPL version 5 · published 2026-07-08 ↗

              DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

            2. 2
              Drugs@FDA application BLA761412 · original submission status AP · 2026-04-29 · dataset 2026-08-13 ↗

              Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

            3. 3
              Langlara (insulin glargine-aldy): BLA 761412 approval letter, April 29, 2026 ↗

              U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

            4. 4
              Lantus (insulin glargine) prescribing information, application 021081 supplements S-078 and S-079, revised June 2023 ↗

              U.S. Food and Drug Administration · Official source · Source checked November 16, 2026